1887

Abstract

Recombinant simian varicella viruses (rSVVs) were engineered to express respiratory syncytial virus (RSV) antigens. The RSV surface glycoprotein G and second matrix protein M2 (22k) genes were cloned into the SVV genome, and recombinant viruses were characterized and . rSVVs were also engineered to express the membrane-anchored or secreted forms of the RSV-G protein as well as an RSV G lacking its chemokine mimicry motif (CX3C), which may have different effects on priming the host immune response. The RSV genes were efficiently expressed in rSVV/RSV-infected Vero cells as RSV-G and -M2 transcripts were detected by RT-PCR, and RSV antigens were detected by immunofluorescence and immunoblot assays. The rSVVs replicated efficiently in Vero cell culture. Rhesus macaques immunized with rSVV/RSV-G and rSVV/RSV-M2 vaccines produced antibody responses to SVV and RSV antigens. The results demonstrate that recombinant varicella viruses are suitable vectors for the expression of RSV antigens and may represent a novel vaccine strategy for immunization against both pathogens.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83453-0
2008-03-01
2021-03-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/3/741.html?itemId=/content/journal/jgv/10.1099/vir.0.83453-0&mimeType=html&fmt=ahah

References

  1. Arnold R., Konig B., Werchau H., Konig W. 2004; Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 330:384–397 [CrossRef]
    [Google Scholar]
  2. Arvin A. M., Mallory S., Moffat J. F. 1999; Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 3:193–200
    [Google Scholar]
  3. Bogger-Goren S., Baba K., Hurley P., Yabuuchi H., Takahashi M., Ogra P. L. 1982; Antibody response in varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis 146:260–265 [CrossRef]
    [Google Scholar]
  4. Bukreyev A., Serra M. E., Laham F. R., Melendi G. A., Kleeberger S. R., Collins P. L., Polack F. P. 2006; The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J Virol 80:5854–5861 [CrossRef]
    [Google Scholar]
  5. Byrd L. G., Prince G. A. 1997; Animal models of respiratory syncytial virus infection. Clin Infect Dis 25:1363–1368 [CrossRef]
    [Google Scholar]
  6. Chen M., Hu K. F., Rozell B., Orvell C., Morcin B., Liljestrom P. 2002; Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169:3208–3216 [CrossRef]
    [Google Scholar]
  7. Cohen J. I., Straus J. E., Arvin A. M. 2006; Varicella-zoster virus replication, pathogenesis and management. In Field's Virology , 5th edn. pp 2774–2818Edited by Knipe D. M., Howley P. M., Griffin D. E., Lamb R. A., Martin M. A., Roizman B., Strauss. Philadelphia, PA: Lippincott, Williams & Wilkins;
    [Google Scholar]
  8. Collins P. L., Murphy B. R. 2002; Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296:204–211 [CrossRef]
    [Google Scholar]
  9. Connors M., Kulkarni A. B., Collins P. L., Firestone C. Y., Holmes K. L., Morse H. C. III, Murphy B. R. 1992; Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 66:1277–1281
    [Google Scholar]
  10. Crowe J. E. 1995; Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO programme for vaccine development. Vaccine 13:415–421 [CrossRef]
    [Google Scholar]
  11. Falsey A. R., Hennessey P. A., Formica M. A., Cox C., Walsh E. E. 2005; Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749–1759 [CrossRef]
    [Google Scholar]
  12. Fleming D. M., Pannell R. S., Cross K. W. 2005; Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 59:586–590 [CrossRef]
    [Google Scholar]
  13. Fletcher T. M. III, Gray W. L. 1992; Simian varicella virus: characterization of virion and infected cell polypeptides and the antigenic cross-reactivity with varicella-zoster virus. J Gen Virol 73:1209–1215 [CrossRef]
    [Google Scholar]
  14. Fraticelli P., Sironi M., Bianchi G., D'Ambrosio D., Albanesi C., Stoppacciaro A., Chieppa M., Allavena P., Ruco L. other authors 2001; Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107:1173–1181 [CrossRef]
    [Google Scholar]
  15. Gershon A. A., Steinberg S. P., Gelb L., Borkowsky W., LaRussa P., Farrara A. 1984; Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 252:355–362 [CrossRef]
    [Google Scholar]
  16. Gevrey J. C., Isaac B. M., Cox D. 2005; Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (fractalkine). J Immunol 175:3737–3745 [CrossRef]
    [Google Scholar]
  17. Glezen W. P. 2004; The changing epidemiology of respiratory syncytial virus and influenza: impetus for new control measures. Pediatr Infect Dis J 23:Suppl. 11S202–S206 [CrossRef]
    [Google Scholar]
  18. Gray W. L. 2003; Pathogenesis of simian varicella virus. J Med Virol 70:S4–S8 [CrossRef]
    [Google Scholar]
  19. Gray W. L. 2004; Simian varicella: a model for human varicella-zoster virus infections. Rev Med Virol 14:363–381 [CrossRef]
    [Google Scholar]
  20. Gray W. L., Mahalingam R. 2005; A cosmid-based system for inserting mutations and foreign genes into the simian varicella virus genome. J Virol Methods 130:89–94 [CrossRef]
    [Google Scholar]
  21. Gray W. L., Williams R. J., Chang R., Soike K. F. 1998; Experimental simian varicella virus infection of St. Kitts vervet monkeys. J Med Primatol 27:177–183 [CrossRef]
    [Google Scholar]
  22. Gray W. L., Starnes B., White M. W., Mahalingam R. 2001; The DNA sequence of the simian varicella virus genome. Virology 284:123–130 [CrossRef]
    [Google Scholar]
  23. Grose C. 2005; Varicella vaccination of children in the United States: an assessment after the first decade 1995–2005. J Clin Virol 33:89–98 [CrossRef]
    [Google Scholar]
  24. Harcourt J., Alvarez R., Jones L. P., Henderson C., Anderson L. J., Tripp R. A. 2006; Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176:1600–1608 [CrossRef]
    [Google Scholar]
  25. Heineman T. C., Connelly B. L., Bourne N., Stanberry L. R., Cohen J. 1995; Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 69:8109–8113
    [Google Scholar]
  26. Heineman T. C., Pesnicak L., Mir A. A., Krogmann T., Krudwig N., Cohen J. I. 2004; Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. Vaccine 22:2558–2565 [CrossRef]
    [Google Scholar]
  27. Jin H., Cheng X., Traina-Dorge V., Park H. J., Zhou H., Soike K., Kemble G. 2003; Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647–3652 [CrossRef]
    [Google Scholar]
  28. Johnson T. R., Graham B. S. 1999; Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73:8485–8495
    [Google Scholar]
  29. Johnson T. R., Johnson J. E., Roberts S. R., Wertz G. W., Parker R. A., Graham B. S. 1998; Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72:2871–2880
    [Google Scholar]
  30. Kamiyama T., Sato H., Takahara T., Kageyama S., Shiraki K. 2000; Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J Infect Dis 181:1158–1161 [CrossRef]
    [Google Scholar]
  31. Levin M. J., Gershon A. A., Weinberg A., Song L. Y., Fentin T., Nowak B. Pediatric AIDS Clinical Trial Group 265 Team; 2006; Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 194:247–255 [CrossRef]
    [Google Scholar]
  32. Maher C. F., Hussell T., Blair E., Ring C. J. A., Openshaw P. J. M. 2004; Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect 6:1049–1055 [CrossRef]
    [Google Scholar]
  33. Olszewska W., Suezer Y., Sutter G., Openshaw P. J. M. 2004; Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23:215–221 [CrossRef]
    [Google Scholar]
  34. Openshaw P. J. M., Tregoning J. S. 2005; Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18:541–555 [CrossRef]
    [Google Scholar]
  35. Ou Y., Traina-Dorge V., Davis K. A., Gray W. L. 2007; Recombinant simian varicella vaccines induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 364:291–300 [CrossRef]
    [Google Scholar]
  36. Oxman M. N., Levin M. J., Johnson G. R., Schmader K. E., Straus S. E., Gelb L. D., Arbeit R. D., Simberkoff M. S., Gershon A. A. 2005; A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284 [CrossRef]
    [Google Scholar]
  37. Patel J. A., Nguyen D. T., Revai K., Chonmaitree T. 2007; Role of respiratory syncytial virus in acute otitis media: implications for vaccine and development. Vaccine 25:1683–1689 [CrossRef]
    [Google Scholar]
  38. Phumiamorn S., Sato H., Kamiyama T., Kurokawa M., Shiraki K. 2003; Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine. J Gen Virol 84:287–291 [CrossRef]
    [Google Scholar]
  39. Sasaki K., Kato M., Takahashi T., Ochi S., Ichinose Y., Shiraki K., Asano Y., Iwanaga M., Tsuji T. 2003; Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper cells with a single nasal coadministration in mice. J Med Virol 70:329–335 [CrossRef]
    [Google Scholar]
  40. Shay D. K., Holman R. C., Roosevelt G. E., Clarke M. J., Anderson L. J. 2001; Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183:16–22 [CrossRef]
    [Google Scholar]
  41. Shiraki K., Hayakawa Y., Mori H., Namazue J., Takamizawa A., Yoshida I., Yamanishi K., Takahashi M. 1991; Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol 72:1393–1399 [CrossRef]
    [Google Scholar]
  42. Srikiatkhachorn A., Braciale T. J. 1997; Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186:421–432 [CrossRef]
    [Google Scholar]
  43. Takimoto T., Hurwitz J. L., Coleclough C., Prouser C., Krishnamurthy S., Zhan X., Boyd K., Scroggs R. A., Brown B. other authors 2004; Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 78:6043–6047 [CrossRef]
    [Google Scholar]
  44. Terada K., Niizuma T., Ogita S., Kataoka N. 2002; Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated vaccine. Vaccine 20:3638–3643 [CrossRef]
    [Google Scholar]
  45. Thompson W. W., Shay D. K., Weintraub E., Brammer L., Cox N., Anderson L. J., Fukuda K. 2003; Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186 [CrossRef]
    [Google Scholar]
  46. Tripp R. A., Jones L. P., Haynes L. M., Zheng H., Murphy P. M., Anderson L. J. 2001; CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732–738 [CrossRef]
    [Google Scholar]
  47. Van Drunen Littel-Van den Hurk S., Mapletoft J. W., Arsic N., Kovacs-Nolan J. 2007; Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17:5–34 [CrossRef]
    [Google Scholar]
  48. Wyatt L. S., Whitehead S. S., Venanzi K. A., Murphy B. R., Moss B. 1999; Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18:392–397 [CrossRef]
    [Google Scholar]
  49. Yu H. R., Chen R. F., Hong K. C., Bong C. N., Lee W. I., Kuo H. C., Yang K. D. 2005; IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol 35:3664–3672 [CrossRef]
    [Google Scholar]
  50. Zambon M. C., Stockton J. D., Clewley J. P., Fleming D. M. 2001; Contributions of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 358:1410–1416 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83453-0
Loading
/content/journal/jgv/10.1099/vir.0.83453-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error